Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case report describes a 54-year-old Saudi woman with systemic lupus erythematosus and severe alopecia, where conventional treatments were ineffective. When belimumab was ineffective, baricitinib led to significant improvement in her condition, suggesting further research is needed to evaluate baricitinib's role in managing SLE.

In a study conducted on 257 Latin American patients with alopecia areata, researchers found that the most frequent lesion location was the scalp, affecting 86.1% of participants, and reported multiple associated comorbidities, notably cardiovascular and endocrine diseases, with certain conditions being more common in women.

This study found that in patients with alopecia areata, the number of follicular stelae in skin biopsies varied by clinical type and severity of the disease, but did not correlate with treatment response.

This study found that a combination treatment using oral and topical steroids with topical minoxidil was well-tolerated in children with severe recalcitrant alopecia areata, showing good responses except in alopecia universalis cases.

This study observed that recurrent alopecia areata patients with salmon patches on the nape often had severe disease, particularly alopecia areata ophiasis, which was more common in females.

This review discusses recent therapeutic approaches for alopecia areata, including the use of Janus kinase inhibitors and interleukin-2, and reports no new clinical results.

This study found that patients with alopecia areata have lower levels of RBC folate, correlating negatively with the disease's severity and extent.

This study suggests that human evolution involved accelerated changes in the HR gene, affecting its role in mediating postnatal hair cycling.

This study observed sustained hair regrowth in some patients with alopecia areata and improvement in vitiligo symptoms, indicating a potential role for dupilumab in treating these conditions, particularly when associated with atopic dermatitis.

In this study, researchers observed that among pediatric alopecia areata patients at Dr. M. Djamil General Hospital Padang, patchy alopecia was most common, affecting 80% of cases, with frequent trichoscopic features including yellow dots, black dots, and broken hairs.

This case report describes the successful remission of alopecia universalis in an 11-year-old girl using combined oral Baricitinib and sublingual minoxidil, suggesting potential for similar treatments in pediatric patients.

Bexarotene 1% topical gel helped some patients with alopecia areata regrow hair.

This letter discusses prior findings on prednisone for alopecia areata, agreeing that systemic steroids usually do not change the disease course but contesting that most patients have a poor prognosis.

This review reports on new and effective drug developments for treating severe alopecia areata, including oral baricitinib, but emphasizes that no treatment guarantees permanent remission or works for all patients, with high recurrence rates after stopping medication.

This study found that intramuscular triamcinolone acetonide or pulse therapy effectively treats alopecia areata with manageable side effects, but further strategies are needed to reduce relapse rates.

This review synthesizes cases of biopsy-confirmed alopecia areata occurring in patients using IL-17 or IL-23 inhibitors, suggesting the need for increased awareness and further investigation into this rare adverse event.

This review discusses the clinical characteristics, diagnosis, and treatment of alopecia areata, exploring potential environmental, immunological, and genetic factors involved in its development, but reports no new research findings.

In this study, ritlecitinib showed sustained effectiveness and a favorable safety profile in treating alopecia areata in patients aged 12 and older over 24 months, with improvements observed in hair and eyebrow regrowth and patient satisfaction.

This review highlights that laser and light treatments could serve as safe and effective alternatives to current therapies for alopecia areata, with the excimer laser showing positive results, though further randomized controlled trials are necessary to establish optimal treatment protocols.

This study found that adding allergen immunotherapy to conventional treatment may reduce relapse-related hair loss in house dust mite-allergic alopecia areata patients over a 3-year period.

This study found that total serum IgE levels were elevated in patients with alopecia areata compared to controls, suggesting a possible involvement of IgE and Th2 cytokines in its pathogenesis.

This case report describes a 15-year-old girl with alopecia universalis who experienced scalp hair regrowth after self-medicating with cannabis, suggesting it may have potential as a treatment for autoimmune diseases like alopecia areata.

This review, drawing on scientific literature, explores alopecia areata's pathogenesis and treatment, noting that while therapies like JAK inhibitors show promise, there remains a significant need for more effective and targeted solutions, and a better understanding of the disease mechanisms.

This study observed that intradermal injections of Betamethasone were more effective than topical Clobetazole for treating alopecia areata in children, while Tofacitinib showed higher efficacy in those with atopic dermatitis.

This study reviewed literature and assessed clinical data on treating alopecia areata linked with atopic diseases, finding that therapies like dupilumab, phototherapy, and JAK inhibitors may address overlapping symptoms, suggesting a focus on reducing pharmacological burden and enhancing quality of life.

This review discusses evidence-based treatments for common hair loss forms, noting robust support for androgenetic alopecia therapies but limited long-term data and fewer high-quality studies for alopecia areata and cicatricial alopecias.

This review updated the evidence on various treatments for alopecia areata, finding that minoxidil and high potency corticosteroids showed significant results in patchy AA, but the overall evidence quality was low.

This study found that young patients with severe AA are more prone to nail abnormalities such as pitting and leukonychia, with koilonychia and red spots lunula in more severe cases.

In this study, daily treatment with ritlecitinib for up to 24 months led to significant reductions in high-severity alopecia areata SALT scores among patients aged ≥12 years, including those with severe forms such as alopecia totalis and universalis.

This review analyzes the mechanism and evidence supporting the approved use of ritlecitinib, a JAK3/TEC kinase inhibitor, for treating severe alopecia areata in patients aged 12 and older, highlighting its role in the changing therapeutic landscape of this immune-mediated disease.